RT Journal Article
SR Electronic
T1 Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.28.20164012
DO 10.1101/2020.07.28.20164012
A1 Chivese, Tawanda
A1 Musa, Omran A. H.
A1 Hindy, George
A1 Al-Wattary, Noor
A1 Badran, Saif
A1 Soliman, Nada
A1 Aboughalia, Ahmed T. M.
A1 Matizanadzo, Joshua T.
A1 Emara, Mohamed M.
A1 Thalib, Lukman
A1 Doi, Suhail A. R.
YR 2021
UL http://medrxiv.org/content/early/2021/07/09/2020.07.28.20164012.abstract
AB Objective To synthesize findings from systematic reviews and meta-analyses on the efficacy and safety of chloroquine (CQ) and hydroxychloroquine (HCQ) with or without Azithromycin for treating COVID-19, and to update the evidence using a meta-analysis.Methods A comprehensive search was carried out in electronic databases for systematic reviews, meta-analyses and experimental studies which investigated the efficacy and safety of CQ, HCQ with or without Azithromycin to treat COVID-19. Findings from the reviews were synthesised using tables and forest plots and the quality effect model was used for the updated meta-analysis. The main outcomes were mortality, the need for intensive care services, disease exacerbation, viral clearance and occurrence of adverse events.Results Thirteen reviews with 40 primary studies were included. Two meta-analyses reported a high risk of mortality, with ORs of 2.2 and 3.0, and the two others found no association between HCQ and mortality. Findings from two meta-analyses showed that HCQ with Azithromycin increased the risk of mortality, with similar ORs of 2.5. The updated meta-analysis of experimental studies showed that the drugs were not effective in reducing mortality (RR 1.1, 95%CI 1.0-1.3, I2 =0.0%), need for intensive care services (OR 1.1, 95%CI 0.9-1.4, I2 =0.0%), virological cure (OR 1.5, 95%CI 0.5-4.4, I2 =39.6%) or disease exacerbation (OR 1.2, 95%CI 0.3-5.9, I2 =31.9%) but increased the odds of adverse events (OR 12,3, 95%CI 2.5-59.9, I2 =76.6%).Conclusion There is conclusive evidence that CQ and HCQ, with or without Azithromycin are not effective in treating COVID-19 or its exacerbation.Registration PROSPERO: CRD42020191353Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe is no funding to reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon requestCOVID-19Coronavirus Disease-19SARS-CoV-2severe acute respiratory syndrome coronavirus 2HCQhydroxychloroquine,CQchloroquinePRIO-harmsPreferred Reporting Items for Overviews of Systematic Reviews including harms checklistAMSTARAssessing the Methodological Quality of Systematic ReviewsMASTERMethodologicAl STandard for Epidemiological ResearchPRISMAPreferred Reporting Items for Systematic Review and Meta-AnalysisCDSRCochrane Database of Systematic ReviewsCENTRALCochrane Central Register of Controlled TrialsDAREDatabase of Abstracts of Reviews of Effectiveness